Table 2. Results of meta-analysis for Ezrin on prognostic effect in cancer patients.
| Outcome | Variables | No. of studies | Model | Pooled HR(95%) | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2(%) | Pvalue | |||||
| OS | 36 | Random | 1.86(1.51–2.31) | 77.70% | 0.000 | |
| Cancer type | ||||||
| Digestive system cancer | 10 | Random | 1.93(1.31–2.85) | 84.70% | 0.000 | |
| HNSCC | 5 | Fixed | 2.54(1.85–3.49) | 0% | 0.489 | |
| Gynecologic cancer | 5 | Random | 1.86(1.10–3.15) | 71.10% | 0.000 | |
| Osteosarcoma | 4 | Random | 3.16(1.90–5.26) | 47.60% | 0.026 | |
| Hepatobiliary cancer | 3 | Fixed | 1.80(1.27–2.56) | 0% | 0.644 | |
| Bladder cancer | 3 | Fixed | 0.49(0.27–0.78) | 0% | 0.967 | |
| NSCLC | 2 | Fixed | 1.97(1.23–3.18) | 0% | 0.747 | |
| Other | 4 | Random | 1.41(0.51–3.91) | 90.80% | 0.000 | |
| Ethnicity | ||||||
| Caucasian | 15 | Random | 1.41(0.95–2.09) | 81.30% | 0.000 | |
| Asian | 21 | Random | 2.21(1.72–2.83) | 74.80% | 0.000 | |
| Sample source | ||||||
| FFPE | 26 | Random | 2.32(1.84–2.92) | 71.20% | 0.000 | |
| TMA | 10 | Random | 1.02(0.64–1.61) | 85.50% | 0.000 | |
| DFS | 10 | Fixed | 2.55(2.14–3.05) | 15.00% | 0.305 | |
| Cancer type | ||||||
| Osteosarcoma | 4 | Fixed | 2.60(1.90–3.65) | 0% | 0.605 | |
| Digestive system cancer | 2 | Fixed | 2.92(1.80–4.75) | 4.80% | 0.305 | |
| Other | 4 | Random | 2.48(1.70–3.60) | 58.90% | 0.063 | |
| Ethnicity | ||||||
| Caucasian | 5 | Fixed | 3.02(2.17–4.20) | 0% | 0.734 | |
| Asian | 5 | Random | 2.37(2.14–3.05) | 45.60% | 0.119 | |
| Sample source | ||||||
| FFPE | 7 | Random | 2.49(1.97–3.15) | 33.90% | 0.169 | |
| TMA | 3 | Fixed | 2.94(1.90–4.54) | 0% | 0.598 | |
| DSS/MFS | 9 | Random | 2.02(1.13–3.63) | 83.20% | 0.000 | |
| Cancer type | ||||||
| Digestive system cancer | 2 | Fixed | 3.03(2.01–4.56) | 0% | 0.919 | |
| Bladder cancer | 2 | Random | 0.73(0.11–4.65) | 88.50% | 0.003 | |
| Soft tissue sarcomas | 3 | Random | 1.43(0.45–4.57) | 89.60% | 0.000 | |
| Other | 2 | Random | 9.71(1.16–81.04) | 75.30% | 0.044 | |
| Ethnicity | ||||||
| Caucasian | 6 | Random | 1.40(0.61–3.19) | 86.40% | 0.000 | |
| Asian | 3 | Random | 4.18(1.60–10.95) | 77.60% | 0.000 | |
| Sample source | ||||||
| FFPE | 4 | Random | 3.82(2.20–6.64) | 47.70% | 0.125 | |
| TMA | 5 | Random | 1.12(0.46–2.70) | 87.40% | 0.000 | |
Random-effects model was used when p-value for heterogeneity test < 0.05; otherwise, fixed-model was used. I2 the percentage of variability in HR attributable to heterogeneity. Abbreviations: HNSCC: squamous cell carcinoma of the head and neck; NSCLC: nonsmall cell lung cancer; FFPE: formalin-fixed, paraffin-embedded; TMA: tissue microarray.